NMD4C Investigators’ Research Named to Quebec Science Magazine’s Top 10 Discoveries of 2023
The 31st edition of the Quebec Science magazine’s Top 10 Discoveries of the Year has recognized a publication from NMD4C investigators in their 2023 list of top scientific discoveries from Quebec-based researchers.
“Clearance of defective muscle stem cells by senolytics restores myogenesis in myotonic dystrophy type 1” is published in Nature Communications, from Dr. Elise Duchesne, Dr. Nicolas Dumont, and Dr. Cynthia Gagnon as a co-author.
Check out the Quebec Science magazine’s article here (available in French), or read the full publication in the journal of Nature Communications.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.